Novo Nordisk reached an important R&D milestone on May 14, announcing a deal worth up to $2.2 billion with Septerna to develop drugs to treat obesity and other cardiometabolic diseases.

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

The prospect of reducing the risk of some very common cancers adds the weight of evidence behind the GLP-1 agonist class, ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In fact, most contractors said developers are struggling to put deals together — same as in 2023 and 2024. A few of the reasons: still-elevated interest rates, higher labor and materials costs ...

As of 3:01:15 pm GMT+2. Market open.